Jasper Therapeutics, Inc.JSPRNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank20
3Y CAGR-49.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-49.4%/yr
Annual compound
Percentile
P20
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2024 | 7.79% |
| 2023 | 49.55% |
| 2022 | 36.21% |
| 2021 | 60.05% |
| 2020 | 339.00% |
| 2019 | 0.00% |